Summary
Bristol-Myers Squibb Company (BMY) filed a Form 8-K on April 25, 2013, to announce its financial results for the first quarter of 2013. The primary purpose of this filing is to provide investors with the company's performance and financial condition as of and for the period ended March 31, 2013. This report includes a press release detailing the Q1 2013 financial results and supplemental information available on the company's website. Investors should review these documents to understand BMY's revenue, profitability, and any significant operational developments during the first quarter of 2013, as these factors directly impact the company's valuation and future prospects.
Key Highlights
- 1Bristol-Myers Squibb announced its first quarter 2013 financial results on April 25, 2013.
- 2The filing serves as a notification of the company's financial performance for the period ending March 31, 2013.
- 3The press release containing the Q1 2013 financial results is furnished as Exhibit 99.1.
- 4Additional supplemental information is provided on the company's website, furnished as Exhibit 99.2.
- 5This report is a standard disclosure to inform stakeholders about the company's operational and financial status.
- 6Investors can find detailed performance metrics, including revenue and earnings, within the furnished press release and supplemental materials.
Frequently Asked Questions
The main purpose of this Form 8-K filing is to announce Bristol-Myers Squibb's financial results for the first quarter of 2013 and to provide investors with access to the press release and supplemental information detailing these results.
The specific financial results for Q1 2013 can be found in the press release dated April 25, 2013 (Exhibit 99.1) and the supplemental information posted on the company's website at www.bms.com (Exhibit 99.2), both of which are furnished with this 8-K filing.
Supplemental materials often include more detailed financial data, segment information, product sales breakdowns, and potentially non-GAAP financial measures or reconciliations that provide further context to the reported financial results. Investors should refer to Exhibit 99.2 for the specific details provided by BMY.